Papp K, Maari C, Cauthen A, et al. - Given that long-term safety and of ixekizumab [160 mg at week 0, then 80 mg every 2 weeks (Q2W) for 12 weeks, followed by every 4 weeks (Q4W) thereafter (ie, Q2W/Q4W), which is the labelled psoriasis dosing where approved, except in Japan] have been established for the treatment of adults with moderate-to-severe plaque psoriasis, however, some patients may benefit from remaining on Q2W dosing beyond 12 weeks, researchers ascertained if patients with static Physician's Global Assessment (sPGA) > 1 at week 12 benefited from receiving more frequent dosing beyond the first 12 weeks. In the integrated data from the UNCOVER-1, UNCOVER-2 and UNCOVER-3 trials, the effectiveness through week 52 of continuous Q2W dosing in the IXORA-P study was contrasted indirectly with Q2W/Q4W in patients with sPGA > 1 at week 12. Among individuals who did not have clear or almost clear skin at week 12, almost 30% more patients who were treated continuously with ixekizumab Q2W in IXORA-P had clear or nearly clear skin at week 52 relative to those treated indirectly using the labelled psoriasis dosing in integrated UNCOVER studies.